Urogenital - oncology - SA Health Approved Cancer Chemotherapy Protocol Register


Bladder

Bladder
Protocol Administration at chemotherapy unit level Review Date
Advanced, metastatic or recurrent pembrolizumab Low February 2022
Bladder intravesical BCG (OncoTICE) Low August 2024
Bladder intravesical gemcitabine High August 2024
Bladder intravesical mitomycin High February 2023
Bladder intravesical mitomycin single dose post TURBT High August 2022
Bladder/Urothelial adjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin cISplatin) Medium August 2024
Bladder/Urothelial fluorouracil and mitomycin chemoradiation Medium2 Day 1. Low Day 22# August 2024
Bladder/Urothelial locally advanced definitive cISplatin (weekly) chemoradiation Medium# August 2025
Bladder/Urothelial locally advanced or metastatic cARBOplatin and gemcitabine (Day 1 cARBOplatin) Medium Day 1. Low day 8 August 2024
Bladder/Urothelial locally advanced or metastatic cISplatin and gemcitabine Medium Day 1. Low day 8 August 2024
Bladder/Urothelial metastatic MVAC (methotrexate vinBLASTine DOXOrubicin cISplatin) Medium August 2024
Bladder/Urothelial neoadjuvant cISplatin and gemcitabine Medium August 2025
Bladder/Urothelial neoadjuvant ddMVAC (dose dense methotrexate vinBLASTine DOXOrubicin cISplatin) Medium August 2024
Bladder/Urothelial small cell cARBOplatin and etoposide Medium August 2025
Bladder/Urothelial small Cell cISplatin and etoposide Medium August 2025

Prostate

Prostate
Protocol Administration at chemotherapy unit level Review Date
Prostate locally advanced or metastatic degarelix Low August 2024
Prostate metastatic bicalutamide Low August 2022
Prostate metastatic cabazitaxel three weekly and prednisolone Medium August 2024
Prostate metastatic castration resistant abiraterone and prednisolone Low August 2024
Prostate metastatic castration sensitive abiraterone and prednisolone Low August 2022
Prostate metastatic castration sensitive DOCEtaxel three weekly Medium August 2024
Prostate metastatic cyproterone Low August 2022
Prostate metastatic denosumab Low August 2024
Prostate Metastatic DOCEtaxel three weekly and prednisolone Medium August 2024
Prostate metastatic enzalutamide Low August 2024
Prostate metastatic flutamide3 Low August 2022
Prostate metastatic goserelin Low August 2024
Prostate metastatic leuprorelin (Eligard) Low August 2024
Prostate metastatic leuprorelin (Lucrin) Low August 2024
Prostate metastatic nilutamide Low August 2022
Prostate metastatic zoledronic acid Low August 2024

Renal

Renal
Protocol Administration at chemotherapy unit level Review Date
Metastatic nivolumab (flat dosing) Low August 2021
Metastatic nivolumab (weight based dosing)
Low August 2021
Metastatic nivolumab maintenance (flat dosing) following ipilimumab and nivolumab Low August 2022
Metastatic nivolumab maintenance (weight based dosing) following ipilimumab and nivolumab Low August 2022
Renal cell metastatic axitinib Low August 2021
Renal cell metastatic cabozantinib Low August 2021
Renal cell metastatic everolimus Low August 2024
Renal cell metastatic ipilimumab and nivolumab (induction) Medium August 2022
Renal cell metastatic pazopanib Low August 2024
Renal cell metastatic sorafenib Low August 2024
Renal cell metastatic sunitinib Low August 2024
Renal cell metastatic temsirolimus3 Low August 2024

Testicular

Testicular
Protocol Administration at chemotherapy unit level Review Date
Testicular germ cell advanced or metastatic EP (etoposide cISplatin) Medium August 2025
Testicular germ cell metastatic BEP (bleomycin etoposide cISplatin) Medium August 2024
Testicular germ cell metastatic VIP (etoposide IFOSFamide cISplatin) High August 2024
Testicular germ cell non seminoma adjuvant BEP (bleomycin etoposide cISplatin) Medium August 2024
Testicular germ cell recurrent TIP (PACLItaxel IFOSFamide cISplatin) High August 2024
Testicular germ cell recurrent VeIP (vinBLASTine IFOSFamide cISplatin) Medium/High August 2024
Testicular germ cell seminoma adjuvant cARBOplatin Medium August 2024

Notes

  1. Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
  2. Fluorouracil pumps may be connected/disconnected at low-risk units
  3. Non-formulary drug included in the protocol
  4. Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.